Mono Pharmacare Limited
NNSE:MONOPHARMA8.90
INR
+0.40
(+4.71%)
ISIN
INE0OIP01012
Return %
Stock
S&P 500
1Y
-58.99
14.20
3Y
-76.20
81.12
5Y
- -
68.34
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Semi-annual Revenue
INR
•
in mil. unless spec.Semi-annual Earnings Per Share
INR
•
in mil. unless spec.Semi-annual Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Panilam Lakhatariya
- Full Time Employees
- 64
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Krinkal Apartment Ahmedabad GU India 380007
- IPO Date
- Sep 7, 2023
- Website
- monopharmacareltd.com
- Similar Companies
- Business
- Mono Pharmacare Limited (MONOPHARMA.NS) is a pharmaceutical distribution and marketing company engaged in the supply of a wide array of healthcare products and medicines across India. The company offers antibiotic medicines, cough cold and anti-allergic medicines, antifungal medicines, nutraceutical medicines, analgesic and antipyretic medicines, antacid and antiemetic medicines, cardiac and diabetic medicines, cosmo care products, bronchodilators, probiotics, antiseptics, and antihistamines; it markets products under its brand "DLS Export" manufactured by third-party WHO/ISO/GMP-certified vendors. Headquartered in Ahmedabad, Gujarat, the company originated from a partnership firm Mono Chemist established in 1994, with roots tracing back to 1964, and was incorporated as a public limited company on October 17, 2022. The company operates primarily in the healthcare pharmaceuticals and biotechnology sector, serving doctors, pharmacies, and healthcare providers in more than 12 states across India, with expansion plans into international markets including through Supal Trading LLC in Dubai. It maintains subsidiaries such as Supal Distributors LLP (99% owned) and Ahmedabad Medical Corporation (99% owned), both focused on pharmaceutical sales and purchases. In recent developments, Mono Pharmacare listed on the NSE SME Emerge platform following an IPO in August 2023 that raised Rs 14.84 crore through 5.3 million equity shares. The company acquired promoter-related entities including DLS Export and integrated operations from Mono Chemist (taken over in 2018) and Ahmedabad Medical Corporation (2020) to consolidate its distribution network. In January 2025, it appointed Drashti Rohit Chande as an additional independent director, and in 2025 approved material related party transactions up to Rs 320 crore annually with entities like Supal Pharma, Supal Pharmacare Ltd, and subsidiaries for sales and purchases in the ordinary course of business.